Skip to main content

Luxia Scientific and Life Genomics enter into a partnership to commercialize microbiome-based tests in the Nordic countries.

Pressmeddelande   •   Mar 15, 2019 05:55 CET

Luxia Scientific and Life Genomics enter into a partnership for microbiom test

Luxia Scientific, a French biotech dedicated to improving wellbeing and health for all through the analysis and understanding of the microbiome, announced today that it has signed an exclusive distribution agreement with Life Genomics to commercialize «1test1TM» in Nordic countries (Denmark, Finland, Iceland, Norway and Sweden). The test was launched in France in October 2018 and in Luxembourg in November 2018.

Reminder:
«1test1TM» is a CE-marked In Vitro Diagnostics test, aimed at analysing the bacterial content of the gut microbiome. «1test1TM» provides bacterial diversity, as well as the relative abundance of many bacterial groups that have been selected for their beneficial role in health.

Luxia Scientific by signing an exclusive distribution agreement with Life Genomics expands its market to the Nordic countries. Life Genomics will be the official distributor of the test in Sweden, where this company is based, and also in Denmark, Finland, Iceland and Norway. 

"“Our partnership with Life Genomics is a recognition of the quality of our products and our expertise in metagenomics. We are looking forward to working together and to extend the sales of «1test1TM» to the Scandinavian market. This partnership will allow more clients to benefit from a personalized approach based on their gut microbiome. Life Genomics is a leader in the Nordic market with its genetic tests aimed at the public.” Alessandra Cervino, CEO of Luxia Scientific.

"The Scientists behind Luxia Scientific have studied the microbiome for more than 10 years and are amongst the most experienced in the field. We feel very comfortable with their support to us and wellfounded recommendations how conditions may be improved by dietary and life style changes to those with dysbiosis. The «1test1TM» is a perfect complement to our portfolio of genetic tests for preventive healthcare" Göran Jacobsson, CEO of Life Genomics.

About Luxia Scientific:
Created in June 2018, Luxia Scientific is a biotech, spin-off from the consulting firm of the same name, created by Professor Alessandra Cervino. The company’s mission is to improve well-being and health, through innovative diagnostics targeting the microbiome. Luxia Scientific is supported by the BPI region Ile de France and is affiliated to Medicen pôle de compétitivité santé d’Ile de France.
To find out more visit: www.luxia-scientific.com

About Life Genomics:
Life Genomics is a private genetic laboratory which was founded in 2014 through the spin-off from TATAA Biocenter AB, to develop offers of genetic tests to the healthcare industry and the public. TATAA is one of Europe’s foremost laboratories for genetic analysis in research and is accredited per ISO 17025. TATAA Biocenter is the European leader in nucleic acid analysis using real-time PCR, NGS and micro-chip technology.

Life Genomics, has two tests for now on the market: Non-invasive prenatal tests (NIPT) and a SNP-based wellness test (LifeNutritest). Life Genomics also launched two new products in 2019. Carrier screening which is an excellent complement to NIPT in their offer for family planning. Also, a gene test for Alzheimer’s risk. Life Genomics clients include healthcare, wellness shops and pharmacies. The Life Genomics laboratory is located in Gothenburg, Sweden.

To find out more visit: www.lifegenomics.se

Life Genomics genetiska analyser grundas på forskning vid Chalmers Tekniska Högskola och TATAA Biocenter. Life Genomics är Sveriges ledande privata genanalysföretag och var bl.a. först med att erbjuda CE-IVD godkänd icke-invasiva fosterdiagnostik, NIPT i Europa. Life Genomics grundades 2014 som en avknoppning från TATAA Biocenter. Bland ägarna återfinns statliga Almi Invest, Bure, Vitrolife och TATAA Biocenter.

Kommentarer (0)

Lägg till kommentar

Kommentera

Genom att skicka din kommentar accepterar du att dina personuppgifter behandlas i enlighet med Mynewsdesks Integritetspolicy.